Neuroimages of cerebral amyloid-β (Aβ) accumulation and small vessel disease (SVD) were examined in patients with various types of cognitive disorders using 11C-labeled Pittsburgh Compound B-positron emission tomography (PiB-PET) and magnetic resonance imaging (MRI). The mean cortical standardized uptake value ratio (mcSUVR) was applied for a quantitative analysis of PiB-PET data. The severity of white matter lesions (WML) and enlarged perivascular spaces (EPVS) on MRI were assessed to evaluate complicating cerebral SVD using semiquantitative scales. In homozygous apolipoprotein E ɛ3/ɛ3 carriers, the incidence of more severe WML and EPVS was higher in PiB-positive than PiB-negative patients, indicating that WML and EPVS might be associated with enhanced Aβ accumulation. An association study between PiB-PET and MRI findings revealed that higher WML grades significantly correlate with lower mcSUVRs, especially in the frontal area, indicating that more severe ischemic MRI findings are associated with milder Aβ accumulation among patients with Alzheimer’s disease. In these patients SVD may accelerate the occurrence of cognitive decline and facilitate early recognition of dementia.
ThalDR, RubU, OrantesM, BraakH (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology58, 1791–1800.
AizensteinHJ, NebesRD, SaxtonJA, PriceJC, MathisCA, TsopelasND, ZiolkoSK, JamesJA, SnitzBE, HouckPR, BiW, CohenAD, LoprestiBJ, DeKoskyST, HalliganEM, KlunkWE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol65, 1509–1517.
6.
Jack CRJr, LoweVJ, SenjemML, WeigandSD, KempBJ, ShiungMM, KnopmanDS, BoeveBF, KlunkWE, MathisCA, PetersenRC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain131, 665–680.
7.
KivipeltoM, HelkalaEL, LaaksoMP, HanninenT, HallikainenM, AlhainenK, SoininenH, TuomilehtoJ, NissinenA (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: Longitudinal, population based study. BMJ322, 1447–1451.
ChengG, HuangC, DengH, WangH (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern Med J42, 484–491.
10.
KemppainenN, JohanssonJ, TeuhoJ, ParkkolaR, JoutsaJ, NganduT, SolomonA, StephenR, LiuY, HanninenT, PaajanenT, LaatikainenT, SoininenH, JulaA, RokkaJ, RissanenE, VahlbergT, PeltoniemiJ, KivipeltoM, RinneJO (2017) Brain amyloid load and its associations with cognition and vascular risk factors in FINGER study. Neurology90, e206–e213.
11.
AbrahamHM, WolfsonL, MoscufoN, GuttmannCR, KaplanRF, WhiteWB (2016)Cardiovascular risk factors and small vessel disease of the brain: Bloodressure, white matter lesions, and functional decline in older persons. J Cereb Blood Flow Metab36, 132–142 .
12.
PantoniL, PoggesiA, InzitariD (2007) The relation between white-matter lesions and cognition. Curr Opin Neurol20, 390–397.
13.
PotterGM, ChappellFM, MorrisZ, WardlawJM (2015) Cerebral perivascular spaces visible on magnetic resonance imaging: Development of a qualitative rating scale and its observer reliability. Cerebrovasc Dis39, 224–231.
14.
ProvenzanoFA, MuraskinJ, TostoG, NarkhedeA, WassermanBT, GriffithEY, GuzmanVA, MeierIB, ZimmermanME, BrickmanAM (2013) White matter hyperintensities and cerebral amyloidosis: Necessary and sufficient for clinical expression of Alzheimer disease?JAMA Neurol70, 455–461.
15.
ZhouY, YuF, DuongTQ (2015) White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer’s disease patients. J Magn Reson Imaging41, 102–109.
16.
RoseboroughA, RamirezJ, BlackSE, EdwardsJD (2017) Associations between amyloid beta and white matter hyperintensities: A systematic review. Alzheimers Dement13, 1154–1167.
17.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
18.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
19.
DuboisB, SlachevskyA, LitvanI, PillonB (2000) The FAB: A Frontal Assessment Battery at bedside. Neurology55, 1621–1626.
20.
NasreddineZS, PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
21.
FujiwaraY, SuzukiH, YasunagaM, SugiyamaM, IjuinM, SakumaN, InagakiH, IwasaH, UraC, YatomiN, IshiiK, TokumaruAM, HommaA, NasreddineZ, ShinkaiS (2010) Brief screening tool for mild cognitive impairment in older Japanese: Validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int10, 225–232.
22.
SheikhJI, YesavageJA, BrooksJO3rd, FriedmanL, GratzingerP, HillRD, ZadeikA, CrookT (1991) Proposed factor structure of the Geriatric Depression Scale. Int Psychogeriatr3, 23–28.
23.
LawtonMP, BrodyEM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist9, 179–186.
24.
FazekasF, ChawlukJB, AlaviA, HurtigHI, ZimmermanRA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol149, 351–356.
25.
MacLullichAM, WardlawJM, FergusonKJ, StarrJM, SecklJR, DearyIJ (2004) Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry75, 1519–1523.
26.
MathisCA, WangY, HoltDP, HuangGF, DebnathML, KlunkWE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem46, 2740–2754.
27.
IkedaM, TashiroY, TakaiE, KuroseS, FugamiN, TsudaK, ArisakaY, KodairaS, FujitaY, MakiokaK, MizunoY, ShimadaH, HarigayaY, TakatamaM, AmariM, YamazakiT, YamaguchiH, HiguchiT, OkamotoK, TsushimaY, IkedaY (2014) CSF levels of Abeta1-38/Abeta1-40/Abeta1-42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer’s disease. Amyloid21, 238–245.
28.
LoprestiBJ, KlunkWE, MathisCA, HogeJA, ZiolkoSK, LuX, MeltzerCC, SchimmelK, TsopelasND, DeKoskyST, PriceJC (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med46, 1959–1972.
29.
McNameeRL, YeeSH, PriceJC, KlunkWE, RosarioB, WeissfeldL, ZiolkoS, BergincM, LoprestiB, DekoskyS, MathisCA (2009) Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med50, 348–355.
30.
YamaneT, IshiiK, SakataM, IkariY, NishioT, IshiiK, KatoT, ItoK, SendaM (2017) Inter-rater variability of visual interpretation and comparison with quantitative evaluation of (11)C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging44, 850–857.
31.
WenhamPR, PriceWH, BlandellG (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet337, 1158–1159.
32.
National Institute on Aging/Alzheimer’s Association Working Group (1996) Apolipoprotein E genotyping in Alzheimer’s disease. Lancet347, 1091–1095.
33.
GodinO, TzourioC, MaillardP, AlperovitchA, MazoyerB, DufouilC (2009) Apolipoprotein E genotype is related to progression of white matter lesion load. Stroke40, 3186–3190.
34.
MahleyRW, RallSCJr (2000) Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet1, 507–537.
35.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
36.
SaundersAM, StrittmatterWJ, SchmechelD, George-HyslopPH, Pericak-VanceMA, JooSH, RosiBL, GusellaJF, Crapper-MacLachlanDR, AlbertsMJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology43, 1467–1472.
37.
SaundersAM (2000) Apolipoprotein E and Alzheimer disease: An update on genetic and functional analyses. J Neuropathol Exp Neurol59, 751–758.
38.
RezekDL, MorrisJC, FullingKH, GadoMH (1987) Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology37, 1365–1368.
39.
ScheltensP, BarkhofF, ValkJ, AlgraPR, van der HoopRG, NautaJ, WoltersEC (1992) White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer’s disease. Evidence for heterogeneity. Brain115, 735–748.
40.
MeyerJS, KawamuraJ, TerayamaY (1992) White matter lesions in the elderly. J Neurol Sci110, 1–7.
41.
KalariaRN (2000) The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging21, 321–330.
42.
McAleeseKE, WalkerL, GrahamS, MoyaELJ, JohnsonM, ErskineD, CollobySJ, DeyM, Martin-RuizC, TaylorJP, ThomasAJ, McKeithIG, De CarliC, AttemsJ (2017) Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol134, 459–473.
43.
RouhlRP, van OostenbruggeRJ, KnottnerusIL, StaalsJE, LodderJ (2008) Virchow-Robin spaces relate to cerebral small vessel disease severity. J Neurol255, 692–696.
44.
YaoM, HerveD, JouventE, DueringM, ReyesS, GodinO, GuichardJP, DichgansM, ChabriatH (2014) Dilated perivascular spaces in small-vessel disease: A study in CADASIL. Cerebrovasc Dis37, 155–163.
45.
ZhuYC, TzourioC, SoumareA, MazoyerB, DufouilC, ChabriatH (2010) Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: A population-based study. Stroke41, 2483–2490.
46.
HirokiM, MiyashitaK (2001) Linear hyperintensity objects on magnetic resonance imaging related to hypertension. Cerebrovasc Dis11, 164–168.
47.
PatankarTF, MitraD, VarmaA, SnowdenJ, NearyD, JacksonA (2005) Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: Study in elderly patients with dementia. AJNR Am J Neuroradiol26, 1512–1520.
48.
VermeerSE, PrinsND, den HeijerT, HofmanA, KoudstaalPJ, BretelerMM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med348, 1215–1222.
49.
EnglerH, ForsbergA, AlmkvistO, BlomquistG, LarssonE, SavitchevaI, WallA, RingheimA, LangstromB, NordbergA (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain129, 2856–2866.
50.
MintunMA, LarossaGN, ShelineYI, DenceCS, LeeSY, MachRH, KlunkWE, MathisCA, DeKoskyST, MorrisJC (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology67, 446–452.
51.
EdisonP, ArcherHA, HinzR, HammersA, PaveseN, TaiYF, HottonG, CutlerD, FoxN, KennedyA, RossorM, BrooksDJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology68, 501–508.
52.
ForsbergA, EnglerH, AlmkvistO, BlomquistG, HagmanG, WallA, RingheimA, LangstromB, NordbergA (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging29, 1456–1465.
53.
KemppainenNM, AaltoS, WilsonIA, NagrenK, HelinS, BruckA, OikonenV, KailajarviM, ScheininM, ViitanenM, ParkkolaR, RinneJO (2006) Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology67, 1575–1580.
54.
GoodheartAE, TamburoE, MinhasD, AizensteinHJ, McDadeE, SnitzBE, PriceJC, MathisCA, LopezOL, KlunkWE, CohenAD (2015) Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities. Neuroimage Clin9, 479–483.
55.
SuzukiK, MasawaN, TakatamaM (2001) Pathogenesis of état criblé in experimental hypertensive rats. J Stroke Cerebrovasc Dis10, 106–112.
56.
ZhangX, DingL, YangL, QinW, YuanJ, LiS, HuW (2016) Brain atrophy correlates with severe enlarged perivascular spaces in basal ganglia among lacunar stroke patients. PLoS One11, e0149593.
57.
FazekasF, KleinertR, OffenbacherH, SchmidtR, KleinertG, PayerF, RadnerH, LechnerH (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology43, 1683–1689.
GurolME, ViswanathanA, GidicsinC, HeddenT, Martinez-RamirezS, DumasA, VashkevichA, AyresAM, AurielE, van EttenE, BeckerA, CarmasinJ, SchwabK, RosandJ, JohnsonKA, GreenbergSM (2013) Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study. Ann Neurol73, 529–536.
61.
EsiriMM, NagyZ, SmithMZ, BarnetsonL, SmithAD (1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet354, 919–920.
